JP2009517381A - ユビキチンｃ末端ヒドロラーゼ−ｌ１の新規な使用 - Google Patents

ユビキチンｃ末端ヒドロラーゼ−ｌ１の新規な使用 Download PDF

Info

Publication number
JP2009517381A
JP2009517381A JP2008542245A JP2008542245A JP2009517381A JP 2009517381 A JP2009517381 A JP 2009517381A JP 2008542245 A JP2008542245 A JP 2008542245A JP 2008542245 A JP2008542245 A JP 2008542245A JP 2009517381 A JP2009517381 A JP 2009517381A
Authority
JP
Japan
Prior art keywords
uch
cancer metastasis
inhibitor
screening
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008542245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517381A5 (enExample
Inventor
リ・コンジョ
キム・ヒュンジュン
チョ・ジョンウ
メン・チョルヨン
ナム・ユキュン
リム・サンミ
キム・ヨンメ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sk Corp
Ewha Womans University
Original Assignee
Sk Corp
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Corp, Ewha Womans University filed Critical Sk Corp
Publication of JP2009517381A publication Critical patent/JP2009517381A/ja
Publication of JP2009517381A5 publication Critical patent/JP2009517381A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2008542245A 2005-11-24 2006-11-24 ユビキチンｃ末端ヒドロラーゼ−ｌ１の新規な使用 Pending JP2009517381A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020050113101A KR100732298B1 (ko) 2005-11-24 2005-11-24 유비키틴 ｃ-말단 가수분해제-ｌ1을 이용한 암전이 진단용조성물
PCT/KR2006/004989 WO2007061256A1 (en) 2005-11-24 2006-11-24 Novel use of ubiquitin c-terminal hydrolase-l1

Publications (2)

Publication Number Publication Date
JP2009517381A true JP2009517381A (ja) 2009-04-30
JP2009517381A5 JP2009517381A5 (enExample) 2010-04-08

Family

ID=38067427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542245A Pending JP2009517381A (ja) 2005-11-24 2006-11-24 ユビキチンｃ末端ヒドロラーゼ−ｌ１の新規な使用

Country Status (6)

Country Link
US (1) US20090208508A1 (enExample)
EP (1) EP1993581A4 (enExample)
JP (1) JP2009517381A (enExample)
KR (1) KR100732298B1 (enExample)
CN (1) CN101316605A (enExample)
WO (1) WO2007061256A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027349A2 (en) * 2007-08-24 2009-03-05 Oryzon Genomics Sa Treatment and prevention of neurodegenerative diseases
WO2010123365A1 (en) * 2009-04-24 2010-10-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Increasing the immunogenicity of epithelial cells infected with human papilloma virus (hpv)
KR101384642B1 (ko) * 2012-06-22 2014-04-22 이화여자대학교 산학협력단 Ｎ―말단이 제거된 유비퀴틴 ｃ―말단 가수분해효소―ｌ１（ｎｔ―ｕｃｈ―ｌ１）를 유효성분으로 포함하는 파킨슨병 예방 및 치료용 약학적 조성물
WO2014185561A1 (ko) * 2013-05-13 2014-11-20 이화여자대학교 산학협력단 신규한 화합물 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 ｕｃｈ－ｌ１ 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020110143A1 (en) 2018-11-26 2020-06-04 Rai Balwant Methods, systems, and a kit for diagnosis, detection, monitoring and treatment of traumatic brain injury
CN110684740B (zh) * 2019-08-09 2020-12-08 无锡傲锐东源生物科技有限公司 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用
CN112891542B (zh) * 2021-02-01 2021-11-16 暨南大学 一种包含UCHs抑制剂的药物组合物及其应用
CN113970643B (zh) * 2021-11-23 2023-06-30 北京大学人民医院 检测抗uch-l1表位的自身抗体的试剂在制备sle血清诊断相关产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005272350A (ja) * 2004-03-24 2005-10-06 Vitamin C60 Bioresearch Kk 癌転移阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837529T2 (de) * 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
KR100545076B1 (ko) 2003-01-27 2006-01-24 김현기 인간 원암유전자 ｈｐｐ1 및 이에 의해 코드되는 단백질
WO2004101762A2 (en) * 2003-05-12 2004-11-25 The Regents Of The University Of Michigan Detection and treatment of cancers of the colon
KR100520800B1 (ko) 2003-05-19 2005-10-12 김진우 인간 원암유전자 ｐｉｇ２ 및 이에 의해 코드되는 단백질

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005272350A (ja) * 2004-03-24 2005-10-06 Vitamin C60 Bioresearch Kk 癌転移阻害剤

Also Published As

Publication number Publication date
EP1993581A1 (en) 2008-11-26
CN101316605A (zh) 2008-12-03
KR20070054952A (ko) 2007-05-30
WO2007061256A1 (en) 2007-05-31
US20090208508A1 (en) 2009-08-20
KR100732298B1 (ko) 2007-06-25
EP1993581A4 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
US9850543B2 (en) Biomarkers associated with BRM inhibition
Ma et al. USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis
JP5628807B2 (ja) リジルｔＲＮＡ合成酵素の細胞内水準を調節して癌転移又は癌細胞の移動を調節する方法
Ridnour et al. Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation
US7655402B2 (en) Diagnoses and therapeutics for cancer
JP2009517381A (ja) ユビキチンｃ末端ヒドロラーゼ−ｌ１の新規な使用
US20070141652A1 (en) Isolation of the mitotic spindle matrix and its methods of use
JPWO2016148115A1 (ja) ホスファチジルセリンシンターゼ１阻害剤への応答性を予測する方法
WO2021173712A1 (en) Molecular biomarkers and targets for fuchs' endothelial corneal dystrophy and glaucoma
Ye et al. Knockdown of casein kinase 1E inhibits cell proliferation and invasion of colorectal cancer cells via inhibition of the Wnt/beta-catenin signaling
US9504687B2 (en) Treating Bax(Δ)2-positive cancer with chemotherapies targeting caspase 8
US20080305102A1 (en) Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer
US10768179B2 (en) Method for predicting responsiveness to cancer treatment using p300-inhibiting compound
KR101128297B1 (ko) Ｔｓｐｙｌ５ 유전자 발현을 억제하여 암세포의 화합물 또는 방사선에 대한 민감도를 증진하는 방법
CN112462072A (zh) 一种tmub1蛋白在制备肿瘤免疫抑制分子检测剂中的应用
US20080227734A1 (en) Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment
WO2006108225A1 (en) Method of screening for compounds that modulate cell proliferation
EP4295844A2 (en) Pharmaceutical composition for inhibiting cancer metastasis
Asuzu et al. Phosphoproteomic dysregulation drives tumor proliferation in Cushing’s disease
Ma et al. Kindlin-1 promotes mitophagy by inhibiting PINK1 degradation to enhance hepatocellular carcinoma progression and modulates sensitivity to donafenib
Lapi Identification of novel and direct target genes of p73
Eleonora Identification of novel and direct target genes of p73

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120807